Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma

NCT05140382 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05140382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05140382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination With Anti-cancer Agents in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or Classical Hodgkin Lymphoma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2021
Completion date
February 16, 2024
Enrollment
52 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory classical hodgkins lymphoma, relapsed/refractory peripheral t-cell lymphoma